Related references
Note: Only part of the references are listed.
Article
Medicine, General & Internal
Pembrolizumab versus methotrexate, docetaxel, or cetuximab for recurrent or metastatic head-and-neck squamous cell carcinoma (KEYNOTE-040): a randomised, open-label, phase 3 study
Ezra E. W. Cohen et al.
LANCET (2019)
Article
Pharmacology & Pharmacy
From Clinical Trial Efficacy to Real-Life Effectiveness: Why Conventional Metrics do not Work
Jean-Pierre Boissel et al.
DRUGS-REAL WORLD OUTCOMES (2019)
Article
Medicine, General & Internal
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
R. L. Ferris et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Share Paper
